Clovis Oncology to Announce Second Quarter 2012 Financial Results and Host Webcast Conference Call on August 8

Clovis Oncology to Announce Second Quarter 2012 Financial Results and Host Webcast Conference Call on August 8

<0> Clovis Oncology, Inc.Anna Sussman, 303-625-5022orBreanna Burkart, 303-625-5023 </0>

Clovis Oncology, Inc. (Nasdaq: CLVS) will announce its second quarter 2012 financial results on Wednesday, August 8, 2012, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast on Wednesday, August 8, at 8:30 a.m. ET to discuss the company’s results in greater detail.

The conference call is being webcast and can be accessed from the Clovis Oncology website at . A replay of the webcast will be available for 30 days.

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.